What is your critique of the risk aversion shown by Indian venture capital funds?
Replied byKiran Mazumdar-Shaw
Founder & Executive Chairperson at Biocon
Niche: Health & Wellness
Revenue: Approx. $172 Million/month
Location: Bengaluru, Karnataka, India
Started: 1978
Indian VCs are willing to invest in safe, copycat service companies, but they avoid backing cutting-edge innovation. Pre-revenue and clinical-stage companies cannot list on Indian exchanges to raise scale-up capital, forcing our best innovators to sell their technologies to foreign buyers.
0
From the Full Interview
This answer is part of a full interview with Kiran Mazumdar-Shaw, Founder & Executive Chairperson at Biocon.
Share this Answer
Found this insight valuable? Share it with your network to help others learn from Kiran Mazumdar-Shaw's experience.
Cite This Answer
Use this answer in your research, article, or academic work
Related Answers
How did your father's liberal worldviews shape your early career decisions?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
What was your father's perspective on paying capitation fees to secure a college seat?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
What did the banks get wrong when you were trying to raise capital for Biocon?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
How did your friend's battle with cancer influence your work in oncology biosimilars?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did you choose to bypass the Indian market for your first GLP-1 drug launch?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did you choose your niece Claire as your successor at Biocon?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
What is your approach to hiring?
By Cobi Blumenfeld-Gantz
Health & Wellness
Approx. 8.3 Million/mo